Tyrosine Kinase Inhibitor Imatinib Mesylate as Anticancer Agent for Advanced Ocular Melanoma Expressing Immuno-Istochemical C-KIT (CD 117): Preliminary Results of a Compassionate Use Clinical Trial

Giammaria Fiorentini, S. Rossi, G. Lanzanova, M. Biancalani, A. Palomba, P. Bernardeschi, P. Dentico, U. De Giorgi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates. At oral doses of 200-600 mg, the majority of patients with chronic myeloid leukaemia, Philadelphia chromosome-positive acute lymphoblastic leukemia expressing the BCR-ABL fusion protein and gastrointestinal stromal tumours (GIST) achieve a bio-molecular and clinical response, frequently complete, associated with limited toxicity. Several other human cancers, as small-cell lung carcinoma, melanoma, seminoma, some sarcomas, and adenoid cystic carcinomas may over-express KIT or PDGF-R, and clinical trials to evaluate the role of IM in the treatment of such cancers are currently ongoing. We determined c-KIT with Dako CD 117 antibody in 5 cases of advanced ocular melanoma (OM) and we found positive immuno-reactivity for CD 117 in three patients. We treated all patients with palliative-use IM at the oral dose of 400 mgr daily. We obtained in expressing positive immuno-reactivity for CD 117 patients: a reduction of malignant ascites in one, a partial remission in the neck nodes in another, and progression of liver metastases in the third. Evidences of progression has been reported in the other two patients expressing negative immuno-reactivity for CD 117. We conclude that the effect of IM should be assessed only in OM with positive immuno-histochemical c-kit (CD 117) expression. IM might be a potential therapeutic strategy for these patients.

Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalJournal of Experimental and Clinical Cancer Research
Volume22
Issue number4 SUPPL.
Publication statusPublished - Dec 2003

Fingerprint

Compassionate Use Trials
Antineoplastic Agents
Protein-Tyrosine Kinases
Melanoma
Clinical Trials
Platelet-Derived Growth Factor Receptors
Adenosine Triphosphate
Philadelphia Chromosome
Adenoid Cystic Carcinoma
Seminoma
Gastrointestinal Stromal Tumors
Small Cell Lung Carcinoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ascites
Sarcoma
Tyrosine
Imatinib Mesylate
Neoplasms
Neck

Keywords

  • Imatinib mesylate
  • Immuno-istochemical C-KIT (CD 117)
  • Ocular melanoma
  • Platelet-derived growth factor receptors
  • Tyrosine kinases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tyrosine Kinase Inhibitor Imatinib Mesylate as Anticancer Agent for Advanced Ocular Melanoma Expressing Immuno-Istochemical C-KIT (CD 117) : Preliminary Results of a Compassionate Use Clinical Trial. / Fiorentini, Giammaria; Rossi, S.; Lanzanova, G.; Biancalani, M.; Palomba, A.; Bernardeschi, P.; Dentico, P.; De Giorgi, U.

In: Journal of Experimental and Clinical Cancer Research, Vol. 22, No. 4 SUPPL., 12.2003, p. 17-20.

Research output: Contribution to journalArticle

@article{d3be3192f367481ca92d5c6cb2b7c563,
title = "Tyrosine Kinase Inhibitor Imatinib Mesylate as Anticancer Agent for Advanced Ocular Melanoma Expressing Immuno-Istochemical C-KIT (CD 117): Preliminary Results of a Compassionate Use Clinical Trial",
abstract = "Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates. At oral doses of 200-600 mg, the majority of patients with chronic myeloid leukaemia, Philadelphia chromosome-positive acute lymphoblastic leukemia expressing the BCR-ABL fusion protein and gastrointestinal stromal tumours (GIST) achieve a bio-molecular and clinical response, frequently complete, associated with limited toxicity. Several other human cancers, as small-cell lung carcinoma, melanoma, seminoma, some sarcomas, and adenoid cystic carcinomas may over-express KIT or PDGF-R, and clinical trials to evaluate the role of IM in the treatment of such cancers are currently ongoing. We determined c-KIT with Dako CD 117 antibody in 5 cases of advanced ocular melanoma (OM) and we found positive immuno-reactivity for CD 117 in three patients. We treated all patients with palliative-use IM at the oral dose of 400 mgr daily. We obtained in expressing positive immuno-reactivity for CD 117 patients: a reduction of malignant ascites in one, a partial remission in the neck nodes in another, and progression of liver metastases in the third. Evidences of progression has been reported in the other two patients expressing negative immuno-reactivity for CD 117. We conclude that the effect of IM should be assessed only in OM with positive immuno-histochemical c-kit (CD 117) expression. IM might be a potential therapeutic strategy for these patients.",
keywords = "Imatinib mesylate, Immuno-istochemical C-KIT (CD 117), Ocular melanoma, Platelet-derived growth factor receptors, Tyrosine kinases",
author = "Giammaria Fiorentini and S. Rossi and G. Lanzanova and M. Biancalani and A. Palomba and P. Bernardeschi and P. Dentico and {De Giorgi}, U.",
year = "2003",
month = "12",
language = "English",
volume = "22",
pages = "17--20",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Tyrosine Kinase Inhibitor Imatinib Mesylate as Anticancer Agent for Advanced Ocular Melanoma Expressing Immuno-Istochemical C-KIT (CD 117)

T2 - Preliminary Results of a Compassionate Use Clinical Trial

AU - Fiorentini, Giammaria

AU - Rossi, S.

AU - Lanzanova, G.

AU - Biancalani, M.

AU - Palomba, A.

AU - Bernardeschi, P.

AU - Dentico, P.

AU - De Giorgi, U.

PY - 2003/12

Y1 - 2003/12

N2 - Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates. At oral doses of 200-600 mg, the majority of patients with chronic myeloid leukaemia, Philadelphia chromosome-positive acute lymphoblastic leukemia expressing the BCR-ABL fusion protein and gastrointestinal stromal tumours (GIST) achieve a bio-molecular and clinical response, frequently complete, associated with limited toxicity. Several other human cancers, as small-cell lung carcinoma, melanoma, seminoma, some sarcomas, and adenoid cystic carcinomas may over-express KIT or PDGF-R, and clinical trials to evaluate the role of IM in the treatment of such cancers are currently ongoing. We determined c-KIT with Dako CD 117 antibody in 5 cases of advanced ocular melanoma (OM) and we found positive immuno-reactivity for CD 117 in three patients. We treated all patients with palliative-use IM at the oral dose of 400 mgr daily. We obtained in expressing positive immuno-reactivity for CD 117 patients: a reduction of malignant ascites in one, a partial remission in the neck nodes in another, and progression of liver metastases in the third. Evidences of progression has been reported in the other two patients expressing negative immuno-reactivity for CD 117. We conclude that the effect of IM should be assessed only in OM with positive immuno-histochemical c-kit (CD 117) expression. IM might be a potential therapeutic strategy for these patients.

AB - Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates. At oral doses of 200-600 mg, the majority of patients with chronic myeloid leukaemia, Philadelphia chromosome-positive acute lymphoblastic leukemia expressing the BCR-ABL fusion protein and gastrointestinal stromal tumours (GIST) achieve a bio-molecular and clinical response, frequently complete, associated with limited toxicity. Several other human cancers, as small-cell lung carcinoma, melanoma, seminoma, some sarcomas, and adenoid cystic carcinomas may over-express KIT or PDGF-R, and clinical trials to evaluate the role of IM in the treatment of such cancers are currently ongoing. We determined c-KIT with Dako CD 117 antibody in 5 cases of advanced ocular melanoma (OM) and we found positive immuno-reactivity for CD 117 in three patients. We treated all patients with palliative-use IM at the oral dose of 400 mgr daily. We obtained in expressing positive immuno-reactivity for CD 117 patients: a reduction of malignant ascites in one, a partial remission in the neck nodes in another, and progression of liver metastases in the third. Evidences of progression has been reported in the other two patients expressing negative immuno-reactivity for CD 117. We conclude that the effect of IM should be assessed only in OM with positive immuno-histochemical c-kit (CD 117) expression. IM might be a potential therapeutic strategy for these patients.

KW - Imatinib mesylate

KW - Immuno-istochemical C-KIT (CD 117)

KW - Ocular melanoma

KW - Platelet-derived growth factor receptors

KW - Tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=1842583423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842583423&partnerID=8YFLogxK

M3 - Article

C2 - 16767900

AN - SCOPUS:1842583423

VL - 22

SP - 17

EP - 20

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 4 SUPPL.

ER -